Clinical TrialApr 30, 2026, 07:07 AM
RDHL RHB-204 shows comparable efficacy to RHB-104 for Crohn's Disease
AI Summary
RedHill Biopharma announced new in vitro data showing its next-generation drug, RHB-204, has comparable Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy to RHB-104 for Crohn's disease. This was achieved with lower doses of active ingredients, suggesting reduced toxicity and side effects. RHB-104 previously showed 64% greater efficacy in a Phase 3 study. A Phase 2 study for RHB-204 in MAP-positive CD patients is planned, with non-dilutive funding being pursued, highlighting significant market potential and existing regulatory designations.
Key Highlights
- RHB-204 demonstrated comparable MAP killing efficacy to RHB-104 in in vitro tests.
- Efficacy achieved with lower doses of two active ingredients, indicating potential for reduced toxicity.
- RHB-104 previously showed 64% greater efficacy than standard of care in Phase 3 CD study (p=0.0048).
- Planned Phase 2 study for RHB-204 targets MAP-positive Crohn's disease patients.
- Non-dilutive funding is being pursued, with grant application submitted.
- RHB-204 patent protected through 2041; holds FDA Fast Track, Orphan Drug, QIDP, and EU Orphan Designations.
- Crohn's disease market expected to grow from $13.6B (2024) to over $19B (2033).
Price Impact
More from RDHL